QQ登录
微博登录
微信登录
新科学想法 › 文献管理 › 浏览文献

有读书笔记Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules

dangdang 添加于 2011-11-24 21:21 | 1986 次阅读 | 0 个评论

  •  作 者

    Makoto Mitsunaga, 1 Mikako Ogawa, 1 Nobuyuki Kosaka, 1 Lauren T Rosenblum, 1 Peter L Choyke1 & Hisataka Kobayashi1

  •  摘 要

    Three major modes of cancer therapy (surgery, radiation and chemotherapy) are the mainstay of modern oncologic therapy. To minimize the side effects of these therapies, molecular-targeted cancer therapies, including armed antibody therapy, have been developed with limited success. In this study, we have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was induced immediately after irradiating mAb-IR700–bound target cells with NIR light. We observed in vivo tumor shrinkage after irradiation with NIR light in target cells expressing the epidermal growth factor receptor. The mAb-IR700 conjugates were most effective when bound to the cell membrane and produced no phototoxicity when not bound, suggesting a different mechanism for PIT as compared to conventional photodynamic therapies. Target-selective PIT enables treatment of cancer based on mAb binding to the cell membrane.

  •  详细资料

    • 文献种类:期刊
    • 期刊名称: nature

  • 相关链接  URL 

  •  dangdang 的文献笔记  订阅

    一种选择性杀死癌细胞的新方法——光免疫治疗法
    研究人员发明了一种选择性杀死癌细胞的新方法——光免疫治疗法，新成果发表在11月在线出版的《自然—医学》期刊上。
     
    尽管手术、放射性治疗和化学治疗是今天癌症治疗的主要方法，但研究人员们逐步成功开发出针对特定分子的更精确目标治疗法。Hisataka Kobayashi和同事将光免疫治疗法作为一种新工具添加到癌症治疗的方法中。这种方法将抗肿瘤抗体与一种对近红外光有反应的分子耦合。他们发现，当用近红外光照射小鼠肿瘤时，癌细胞选择性地死亡了。
     
    尽管在此之前科学家们也研制过其他基于光的治疗方法，但Kobayashi和同事发现了一种重要的不同之处：除非与目标细胞结合在一起，改性抗体没有毒性。这种性能是新技术应用于临床的关键所在。（来源：科学时报 王丹红/编译）
管理选项： 导出文献

评论(0 人)

facelist doodle 涂鸦板

求全文 推荐 收藏
 

1 人收藏

该用户的其他文献

Copyright;  © 新科学想法 2016-2017   浙公网安备 33010202000686号   ( 浙ICP备09035230号-1 )